Positron Emission Tomography: applications in drug discovery and drug development.
about
19F magnetic resonance imaging of perfluorocarbons for the evaluation of response to antibiotic therapy in a Staphylococcus aureus infection modelDevelopment of New Deoxycytidine Kinase Inhibitors and Noninvasive in Vivo Evaluation Using Positron Emission TomographyCNS animal fMRI in pain and analgesia.Molecular imaging: current status and emerging strategies.Bioluminescence and 19F magnetic resonance imaging visualize the efficacy of lysostaphin alone and in combination with oxacillin against Staphylococcus aureus in murine thigh and catheter-associated infection models.Application of palladium-mediated (18)F-fluorination to PET radiotracer development: overcoming hurdles to translation.Quinolinic acid induced neurodegeneration in the striatum: a combined in vivo and in vitro analysis of receptor changes and microglia activation.Performance evaluation of an Inveon PET preclinical scanner.Can Functional Magnetic Resonance Imaging Improve Success Rates in CNS Drug Discovery?Design and optimization of coin-shaped microreactor chips for PET radiopharmaceutical synthesisIntravenous delivery of targeted liposomes to amyloid-β pathology in APP/PSEN1 transgenic mice.Molecular imaging of neuroblastoma progression in TH-MYCN transgenic mice.Modern imaging technologies in toxicologic pathology: An overview.Recent development in PET instrumentation.Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics.Enhanced selective serotonin re-uptake inhibitors as antidepressants: 2004 - 2006.[(11) C]Carbon monoxide in labeling chemistry and positron emission tomography tracer development: scope and limitations.Flow optimization study of a batch microfluidics PET tracer synthesizing device.Rapid and efficient synthesis of [11C]ureas via the incorporation of [11C]CO2 into aliphatic and aromatic amines.Synthesis of the positron-emitting radiotracer [(18)F]-2-fluoro-2-deoxy-D-glucose from resin-bound perfluoroalkylsulfonates.Preclinical anaylses of [18F]cEFQ as a PET tracer for imaging metabotropic glutamate receptor type 1 (mGluR1).
P2860
Q27318705-ADE63127-19F8-4547-86F0-7ED5A43A4ADDQ27679693-1306C059-BC9D-4FDC-98AC-5024675E7CF5Q30469133-313E90B9-77FA-42E3-A086-DEB8C4F80B97Q30474579-5C31EABE-6C6D-4AAA-B43B-003E7FD7AF5AQ30574330-D2D9C45D-79F4-42D4-806F-93C2F83611CBQ31114482-FB7A979A-9AE8-48CA-A932-10E26DD5AD9DQ33310422-CDF2AFA0-1B3E-4F10-B7B7-874A45B31DABQ33728565-DFB91664-0B0C-47B5-A61C-8C564FAAAC41Q33963735-F54103D5-94E2-4CD5-B596-821508C8F73BQ34397455-4666DA2E-B348-4047-B17C-56A8D7DD7406Q34465222-C49822BE-AAEE-4B93-9846-530C5F95D338Q36673633-C30D60ED-32BB-448E-818D-EF82EFA2B020Q36687999-A25C444A-D34D-4199-8A43-1D25A3386BCFQ36970344-92AED048-F82D-4286-A403-1E307E3606AAQ37236103-D999BC9A-1B23-49E0-97C7-3AF39F9EACD6Q37689787-42A93033-8E24-4F15-B19C-A109977C1216Q38358708-4AD48ED4-B76D-46D0-86EA-B3FEEDABC156Q42582019-51516A0F-E5F0-46F3-A006-17D041F011CDQ43776076-4CE232E6-857C-4948-BAAD-000B24F3E41AQ46155470-041F41B3-08C5-4258-AAFD-43B690D6AEFDQ48045954-4E6D5F53-F257-4E0B-B33C-3F660958C92F
P2860
Positron Emission Tomography: applications in drug discovery and drug development.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Positron Emission Tomography: applications in drug discovery and drug development.
@ast
Positron Emission Tomography: applications in drug discovery and drug development.
@en
type
label
Positron Emission Tomography: applications in drug discovery and drug development.
@ast
Positron Emission Tomography: applications in drug discovery and drug development.
@en
prefLabel
Positron Emission Tomography: applications in drug discovery and drug development.
@ast
Positron Emission Tomography: applications in drug discovery and drug development.
@en
P1476
Positron Emission Tomography: applications in drug discovery and drug development.
@en
P2093
Jingli Wang
Laura Maurer
P304
P356
10.2174/156802605774297056
P577
2005-01-01T00:00:00Z